BIRB-796 is not an effective ABL(T315I) inhibitor.
O'Hare
Thomas
T
Druker
Brian J
BJ
D001549:Benzamides; D015195:Drug Design; D004926:Escherichia coli / Q000378:metabolism*; D029968:Escherichia coli Proteins / Q000378:metabolism*; D000068877:Imatinib Mesylate; D008832:Microchemistry / Q000379:methods; D009281:Naphthalenes / Q000378:metabolism*; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010879:Piperazines / Q000378:metabolism; D011485:Protein Binding; D025941:Protein Interaction Mapping / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000378:metabolism*; D016315:Proto-Oncogene Proteins c-abl / Q000378:metabolism*; D011720:Pyrazoles / Q000378:metabolism*; D011743:Pyrimidines / Q000378:metabolism; D010671:Phenylurea Compounds
D001549:Benzamides; D029968:Escherichia coli Proteins; D000068877:Imatinib Mesylate; D009281:Naphthalenes; D004364:Pharmaceutical Preparations; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D016315:Proto-Oncogene Proteins c-abl; D011720:Pyrazoles; D011743:Pyrimidines; C452139:doramapimod; D010671:Phenylurea Compounds